The Medical Technology Development Company

recalls related to product quality problems. Observers felt the company would have lost even more

One major benefit why firms like CEMEX will like to go global is to increase their profitability. Exhibit 9 of the case study shows that the operating margin, the EBITDA margin and the EDITDA OF CEMEX kept on increasing. For instance, the EBITDA margin increased from 28.6% in 1998 to 37.1% in 1999. This is highly due to the increase in revenue from the sales of the firm’s products in other countries. You could also see that sales kept on increasing from 1989-1999. Looking at the total sales of CEMEX one will realize that the US accounted for 12% of sales and 7% of EBITDA and it applies to the other countries that CEMEX and the other majors engaged in.

McKesson, now “the world’s largest health care services company,” has a combined customer base of about 5000 hospitals, 25,000 retail pharmacies, 35,000 physician practices, 10,000 extended care sites, 450 pharmaceutical manufactures, and 2000 medical-surgical manufacturers (Chicago tribune 1998). Mckesson has a 13.2% market share of the Health Information Technology industry and employs roughly 37,000 people. Mckesson’s hospital information system solutions includes their electronic health record system (HER, Total Coordinated Care product suite, InterQual Decision support products,

With an importance on maintaining a trade surplus, China has heavy defiance towards foreign imports. Moreover, there is a rising trend of preference towards domestic Chinese countries over foreign companies. For instance, General Order No.95 released by the government needs all medical devices imported into China to go through severe safety inspections. However, the same requirements are not applied to Chinese-made products. Firms wishing to introduce new products into the market have to face significant governmental pressure and wait for typically 12 months to have a new piece of equipment permitted. Similarly, the state in Russia is also quite disapproving. In addition to a great degree of bureaucracy, possible changes to legislation that sought to assist the domestic producers instead of foreign firms are likely to take place. In contrast, import of medical equipment has been progressively growing in India, and is consistently to have steady growth in the following years. The level of import defiance in Brazil is the lowermost midst the four countries as Brazil is greatly dependent on import of medical devices. Unlike the other three markets, import tariffs are low, and there are no import duties or value-added taxes on 42 medical devices. In addition, the product

There is a small exporter of laboratory and industrial centrifuges in Pennsylvania, the company is called Spin Cent. the passive export direction was the primary goal of the company. The reason for an international orientation of Spincent was a difficult US economy. but this gave the company the incentive to focus more and more on international markets. Above all, the issue of standard export was now seen as an ambitious goal. the Asian markets have become a main target for the company, which is still so fresh, because Spincent has existed for the first time in 7 years. Langfrisitg, to establish favorable and solid relationships with a sales network in the region were the efforts of the company.

The reasons for choosing continental European as a global location for Whelan Pharmaceutical as follows:

As it relates to the textbook, this describes some of the scope of the hospitals; which refers to the range of activities which the firm performs internally, the breadth of its product and service offerings, the extent of its geographic market and its mix of businesses. But unlike with the electric company, no regulator caps hospital profits. To the extent that author Steven Brill found any consistency among hospital charge-master practices, this is one of them: hospitals routinely seem to charge 2V2 times what expensive implantable devices cost them, which produces that 150% profit margin.

Extraordinary sales growth for AMT of 30% annually is resulting in major operating losses, and external funds are necessary to be able to continue with this rapid expansion. The net operating losses from 1983-1985 were $1,289,000 in 1983; $1,176,000 in 1984; and $1,487,000 in 1985. The bulk of these losses were a direct result of both

and the foreign distributor, often ensure an extensive portion of the financial costs are absorbed by

Silicon Valley Medical Technologies - SIVMED was found in San Jose, CA, in 1982 by Kelly’s O’Brien, David Roberts, and Barbara Smalley. O’Brien and Roberts, both MDs, were on the research faculty at the UCLA Medical School at the time; O’Brien specialized in biochemistry and molecular biology, and Roberts specialized in immunology and medical microbiology. Smalley, who has a PhD, served as department chair of the Microbiology Department at UC-Berkeley.

Stryker continues to have a consistent flow of new products that expand markets. They just recently bought MAKO Surgical Corp. for $1.65billion, which develops robotic technology for hip and knee replacement surgeries. As long as Stryker continues to develop innovate new products and acquire its competition will continue to gain market share.

Affordable and appropriate medical devices and diagnostics are an integral part of any effective healthcare system- but continue to be a critical unmet need for billions of low-income consumers living in countries like India. This critical need is fast becoming a generational market opportunity, as MedTech expenditure explodes globally, reaching $42 billion in India, and $198 billion in BRICs by 2025- the majority of it from low and mid-income consumers. This market requires a new wave of innovation, resulting in products that address the resource-constraints, skill gaps, and affordability issues endemic in these markets. India can take global leadership in Affordable MedTech Innovation if the right innovation ecosystem is created- both meeting

Various legal frameworks regulate both the domestic and international businesses. As such, the laws and regulations within the United States are somewhat dissimilar to those in the global trade arena. It is worth pointing out that contextual factors among other issues are some of the reasons why trades conducted within the United States markets would be different from the international ones. For a company like Medeco that wishes to consider expansion into the global arena, it would be essential to understanding that the legal regulations it will encounter in its endeavor to operate overseas may be different and challenging. Within the United States, the company would have to comply with the Uniform Commercial Code (UCC). This regulatory framework stipulates and directs how businesses within US are carried out. However, on the international venture, Medeco will need to subscribe to Convention and Contracts for International Sales of Goods (CISG). This is a trade agreement that tow parties from different states enter into as they seek to engage in the sales of goods and services at the international level. For a company in the caliber of Medeco, signing this contract with countries like Germany, France, and China is necessary since it operates from the United States, an agreement between the nation (US) and the respective countries is key in enhancing business operations.

Organization- Medtronic is a company where they want to improve lives by having medical technology. They can create innovations for health systems, hospitals, and healthcare providers so they can help and provide the best care possible to patients and their families around the world. Medtronic is working with health systems to provide and combine our capabilities with their knowledge to help change how the company can work together and to achieve the best results.

The effects of globalization are prevalent in almost all industries world-wide; the pharmaceutical industry is no exception. Through the globalization of markets and production, there has been a dramatic shift in the last several years. Eli Lilly is a leading company in the US and throughout the world, and they’ve had to adapt to the trends that come as a result of globalization including moving operations overseas and capitalizing on advantages present in other markets. The company has done well in this department, as their products are available in over 130 countries. One of their large successes stories was creating a joint-venture with the leading Indian pharmaceutical provider Ranbaxy.